Dr Gough Au
Conjoint Fellow
School of Biomedical Sciences and Pharmacy (Immunology and Microbiology)
- Email:gough.au@newcastle.edu.au
- Phone:(02) 404 20253
Career Summary
Biography
Dr Gough Au is a conjoint Post Doctoral Research Fellow with the University of Newcastle and works for the Australian oncolytic virotherapy company Viralytics Ltd. Dr Au began his career as a NHMRC Industry Research fellow (2007-2011) carrying out research on the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma.
Research Expertise
Oncolytic virotherapy, Virology & Cancer Biology
Teaching Expertise
PHAR6124 Virology Lectures HUBS3204 Lab Professional Skills - Commercialisation of Science and Biotechnology Startup Companies.
Administrative Expertise
Animal Care and Ethics Committee member (2011- to present) Faculty of Health - Work Health and Safety Group.
Collaborations
Gough's main research interest is in the development of naturally occurring viruses with selective anti-cancer properties, for the treatment of melanoma, multiple myeloma and malignant glioma. Other interests include Oncolytic virotherapy, Virology and Cancer Biology.
Qualifications
- PhD, University of Newcastle
- Bachelor of Biomedical Sciences, University of Newcastle
- Bachelor of Biomedical Sciences (Hons), University of Newcastle
Keywords
- Carcinogenesis
- Clinical sciences
- Oncology
- oncolytic virotherapy
- virology
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 110399 | Clinical Sciences not elsewhere classified | 35 |
| 030499 | Medicinal and Biomolecular Chemistry not elsewhere classified | 35 |
| 111299 | Oncology and Carcinogenesis not elsewhere classified | 30 |
Professional Experience
Academic appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 1/05/2007 - 1/04/2011 | Fellow | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
| 1/05/2007 - | NHMRC Industry Fellow | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
| 1/08/2004 - 1/05/2007 |
Research Director Research Director/Post Doctoral Scientist |
The University of Newcastle Research Associates School of Biomedical Sciences and Pharmacy Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (13 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018 |
Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, et al., 'Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus', Molecular Therapy - Oncolytics, 9 1-12 (2018) © 2018 The Authors As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportu... [more] © 2018 The Authors As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeutic virus. This study investigated CVA21-induced cytotoxicity in a panel of human bladder cancer cell lines, revealing a range of sensitivities largely correlating with expression of the viral receptor ICAM-1. CVA21 in combination with low doses of mitomycin-C enhanced CVA21 viral replication and oncolysis by increasing surface expression levels of ICAM-1. This was further confirmed using 300-µm precision slices of NMIBC where levels of virus protein expression and induction of apoptosis were enhanced with prior exposure to mitomycin-C. Given the importance of the immunogenicity of dying cancer cells for triggering tumor-specific responses and long-term therapeutic success, the ability of CVA21 to induce immunogenic cell death was investigated. CVA21 induced immunogenic apoptosis in bladder cancer cell lines, as evidenced by expression of the immunogenic cell death (ICD) determinant calreticulin, and HMGB-1 release and the ability to reject MB49 tumors in syngeneic mice after vaccination with MB49 cells undergoing CVA21 induced ICD. Such CVA21 immunotherapy could offer a potentially less toxic, more effective option for the treatment of bladder cancer.
|
||||||||||
| 2017 |
Sahoo SS, Quah MY, Nielsen S, Atkins J, Au GG, Cairns MJ, et al., 'Inhibition of extracellular matrix mediated TGF-ß signalling suppresses endometrial cancer metastasis.', Oncotarget, 8 (2017) [C1]
|
||||||||||
| 2014 |
McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014) [C1] © 2014 The Authors. Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed f... [more] © 2014 The Authors. Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed from pure mitochondrial DNA (mtDNA) under certain conditions, which is potently proinflammatory. We hypothesized that injury and orthopedic trauma surgery would induce NET production with mtDNA as a structural component. Methods: Neutrophils were isolated 8 trauma patients requiring orthopedic surgery postinjury and up to 5 days postoperatively. Four healthy volunteers provided positive and negative controls. Total hip replacement patients acted as an uninjured surgical control group. Neutrophil extracellular traps were visualized with DNA (Hoechst 33342TM/Sytox Green/MitoSox/MitoTracker) stains using live cell fluorescence microscopy with downstream quantitative polymerase chain reaction analysis of DNA composition. Results: Neutrophil extracellular traps were present after injury in all 8 trauma patients. They persisted for 5 days postoperatively. Delayed surgery resulted in NET resolution, but they reformed postoperatively. Total hip replacement patients developed NETs postoperatively, which resolved by day 5. Quantitative polymerase chain reaction analysis of NET-DNA composition revealed that NETs formed after injury and surgery were made of mtDNA with no detectable nuclear DNA component. Conclusions: Neutrophil extracellular traps formed after major trauma and subsequent surgery contain mtDNA and represent a novel marker of heightened innate immune activation. They could be considered when timing surgery after trauma to prevent systemic NET-induced inflammatory complications.
|
||||||||||
| 2013 |
Kok CC, Au GG, 'Novel marker for recombination in the 3'-untranslated region of members of the species Human enterovirus A', ARCHIVES OF VIROLOGY, 158 765-773 (2013) [C1]
|
||||||||||
| 2011 |
Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
|
||||||||||
| 2009 |
Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
|
||||||||||
| 2008 |
Howland LJ, Au GG, Barry RD, Shafren DR, 'Potent oncolytic activity of human enteroviruses against human prostate cancer', Prostate, 68 577-587 (2008) [C1]
|
||||||||||
| 2007 |
Au GG, Lincz L, Enno A, Shafren DR, 'Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma', British Journal of Haematology, 137 133-141 (2007) [C1]
|
||||||||||
| 2005 |
Au GG, Lindberg AM, Barry RD, Shafren DR, 'Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21', International Journal of Oncology, 26 1471-1476 (2005) [C1]
|
||||||||||
| 2004 |
Hansbro NG, Johansson ES, Au GG, Lindberg A, Barry RD, Shafren DR, 'Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection', Journal of Virology, 78 1431-1439 (2004) [C1]
|
||||||||||
| 2004 |
Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
|
||||||||||
| 2000 |
Tooney PA, Au GG, Chahl LA, 'Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex', Neuroscience Letters, 283 185-188 (2000) [C1]
|
||||||||||
| Show 10 more journal articles | |||||||||||
Conference (14 outputs)
| Year | Citation | Altmetrics | Link | ||||
|---|---|---|---|---|---|---|---|
| 2016 |
Pandha HS, Annels NE, Simpson G, Mostafid H, Harrington KJ, Melcher A, et al., 'Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2016)
|
||||||
| 2016 |
Sahoo SS, Tanwar PS, 'Inhibition of extracellular matrix mediated TGFß signalling suppress endometrial cancer metastasis', Sydney (2016)
|
||||||
| 2015 | Quay M, Wong Y, Au G, Shafren D, 'Immune-checkpoint blockade in combination with a novel oncolytic immunotherapeutic agent, Coxsackievirus A21, significantly reduces tumor growth and tumor rechallenge', EUROPEAN JOURNAL OF CANCER (2015) [E3] | ||||||
| 2014 |
Shafren D, Quah M, Wong Y, Andtbacka RH, Au G, 'Combination of a novel oncolyticimmunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model', Journal for ImmunoTherapy of Cancer, National Harbour, MD (2014) [E3]
|
||||||
| 2014 | Simpson GR, Ajaz M, Launchbury FA, Bolton G, Melcher AA, Harrington KJ, et al., 'Major synergy between Coxsackievirus A21 (CAVATAK (TM)) and radiotherapy or chemotherapy in bladder cancer', HUMAN GENE THERAPY, Lincoln Coll & Examinat Sch, Oxford, ENGLAND (2014) [E3] | ||||||
| 2014 | Wong YVY, Quah MY, Shafren DR, Au GG, 'Synergistic Activity of Coxsackievirus A21 (CVA21) and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)', HUMAN GENE THERAPY, Lincoln Coll & Examinat Sch, Oxford, ENGLAND (2014) [E3] | ||||||
| 2011 | Yee YWV, Chan SHE, Shafren DR, Au GG, 'Oncolytic activity of coxsackievirus A21 in human lung cancer: A novel targeted anti-cancer strategy', Journal of Thoracic Oncology, Amsterdam, The Netherlands (2011) [E3] | ||||||
| 2011 |
Shafren DR, Farrelly M, Croft AJ, Davies B, Stewart J, Ingham R, et al., 'CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
|
||||||
| 2011 | Shafren DR, Au GG, Davies B, Chan E, Stewart J, 'Pre-clinical oncolytic activity of coxsackievirus a21 in pancreatic cancer', Annals of Oncology, Barcelona, Spain (2011) [E3] | ||||||
| 2007 |
Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
|
||||||
| 2006 |
Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
|
||||||
| 2005 |
Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
|
||||||
| 2005 |
Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
|
||||||
| 2000 |
Tooney PA, Au GG, Chahl LA, 'Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain', Proceedings of the Australian Physiological and Pharmacological Society Symposium Tachykinins: The Challenge Continues, Newcastle, Australia (2000) [E1]
|
||||||
| Show 11 more conferences | |||||||
Grants and Funding
Summary
| Number of grants | 9 |
|---|---|
| Total funding | $595,774 |
Click on a grant title below to expand the full details for that specific grant.
20113 grants / $96,500
Maitland Cancer Appeal Committee Donation - Lung Cancer Mouse Model$50,000
Funding body: Maitland Cancer Appeal Committee
| Funding body | Maitland Cancer Appeal Committee |
|---|---|
| Project Team | Professor Phil Hansbro, Laureate Professor Paul Foster, Doctor Gough Au |
| Scheme | Research Project |
| Role | Investigator |
| Funding Start | 2011 |
| Funding Finish | 2011 |
| GNo | G1100246 |
| Type Of Funding | Donation - Aust Non Government |
| Category | 3AFD |
| UON | Y |
SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000
Funding body: NHMRC (National Health & Medical Research Council)
| Funding body | NHMRC (National Health & Medical Research Council) |
|---|---|
| Project Team | Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Joerg Mattes, Associate Professor Simon Keely, Associate Professor Jay Horvat, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Catherine Ptaschinski, Doctor Kelly Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Laureate Professor John Aitken, Conjoint Professor Keith Jones, Laureate Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog |
| Scheme | Equipment Grant |
| Role | Investigator |
| Funding Start | 2011 |
| Funding Finish | 2011 |
| GNo | G1100037 |
| Type Of Funding | Other Public Sector - Commonwealth |
| Category | 2OPC |
| UON | Y |
World Cancer Congress 2011, World Expo Center, Dalian, China, 22 - 25 May 2011$1,500
Funding body: University of Newcastle - Faculty of Health and Medicine
| Funding body | University of Newcastle - Faculty of Health and Medicine |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | Travel Grant |
| Role | Lead |
| Funding Start | 2011 |
| Funding Finish | 2012 |
| GNo | G1100576 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
20101 grants / $85,188
Control of malignant glioma by naturally occurring oncolytic enteroviruses.$85,188
Funding body: Cancer Australia
| Funding body | Cancer Australia |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | Priority-driven Collaborative Cancer Research Scheme |
| Role | Lead |
| Funding Start | 2010 |
| Funding Finish | 2010 |
| GNo | G0190325 |
| Type Of Funding | Aust Competitive - Commonwealth |
| Category | 1CS |
| UON | Y |
20092 grants / $31,700
The use of Coxsackievirus A21 as a therapy for multiple myeloma and malignant glioma$30,000
Funding body: Ramaciotti Foundations
| Funding body | Ramaciotti Foundations |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | Establishment Grant |
| Role | Lead |
| Funding Start | 2009 |
| Funding Finish | 2009 |
| GNo | G0189325 |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | Y |
5th International Meeting on Replicating Oncolytic Virus Therapeutics, Banff Canada, 18-21 March 2009$1,700
Funding body: University of Newcastle - Faculty of Health and Medicine
| Funding body | University of Newcastle - Faculty of Health and Medicine |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | Travel Grant |
| Role | Lead |
| Funding Start | 2009 |
| Funding Finish | 2009 |
| GNo | G0189949 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
20081 grants / $5,379
New Staff Grant$5,379
Funding body: University of Newcastle
| Funding body | University of Newcastle |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | New Staff Grant |
| Role | Lead |
| Funding Start | 2008 |
| Funding Finish | 2008 |
| GNo | G0188610 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
20072 grants / $377,007
Coxsackievirus A21 virotherapy of multiple myeloma and malignant glioma$369,000
Funding body: NHMRC (National Health & Medical Research Council)
| Funding body | NHMRC (National Health & Medical Research Council) |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | Industry Research Fellowships |
| Role | Lead |
| Funding Start | 2007 |
| Funding Finish | 2010 |
| GNo | G0186779 |
| Type Of Funding | Aust Competitive - Commonwealth |
| Category | 1CS |
| UON | Y |
The use of Coxsackie B group viruses as potential treatments for human gastric and colorectal cancers$8,007
Funding body: University of Newcastle
| Funding body | University of Newcastle |
|---|---|
| Project Team | Doctor Gough Au |
| Scheme | Early Career Researcher Grant |
| Role | Lead |
| Funding Start | 2007 |
| Funding Finish | 2007 |
| GNo | G0188074 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
Research Supervision
Number of supervisions
Past Supervision
| Year | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2018 | PhD | Investigation of Coxsackievirus A21 as a Potential Treatment for Pancreatic Cancer | PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
| 2017 | PhD | Investigating the Mechanisms of Tobacco Cigarette Smoke Induced Lung Cancer | PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2016 | PhD | Investigation of Oncolytic Coxsackievirus A21 as a Potential Treatment for Lung Cancer | PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
| 2016 | PhD | Enhancement of Oncolytic Coxsackievirus A21 with Conventional Chemotherapies and Immune Checkpoint Inhibitors for the Treatment of Melanoma | PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
| 2014 | PhD | Low Pathogenic Human Enteroviruses as Novel Anti-Cancer Agents Against Malignant Glioma | PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
Dr Gough Au
Position
Conjoint Fellow
Viralytics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
Focus area
Immunology and Microbiology
Contact Details
| gough.au@newcastle.edu.au | |
| Phone | (02) 404 20253 |
| Fax | (02) 404 20027 |
Office
| Room | 2420 |
|---|---|
| Building | HMRI building |
| Location | Level 2, HMRI Building East Wing , |
Research Networks
Connect with me
